#1 Clinical Trials Search in Europe

Study Comparing Olaparib and Chemotherapy for Patients with Recurrent Ovarian Cancer After Surgery

3 1 1 1

What is this study about?

This clinical trial is focused on studying the effects of a medication called olaparib in patients with recurrent ovarian cancer. The study compares the use of olaparib, which is taken as a tablet, to standard chemotherapy treatments that include medications such as paclitaxel, carboplatin, gemcitabine, doxorubicin, bevacizumab, and cisplatin. These chemotherapy drugs are typically given through an intravenous (IV) infusion.

The purpose of the study is to determine how effective olaparib is in maintaining the health of patients after their cancer has progressed, compared to the standard chemotherapy options. Participants in the study will receive either olaparib or one of the standard chemotherapy treatments after undergoing a surgical procedure known as secondary cytoreductive surgery, which aims to remove as much of the cancer as possible.

The study will follow participants over a period of time to observe their progression-free survival, which means the length of time during and after treatment that a patient lives with the disease without it getting worse. The study will also look at overall survival, safety, and quality of life. Participants will be randomly assigned to receive either olaparib or one of the standard chemotherapy treatments, and some may receive a placebo. The study is designed to provide valuable information on the best treatment options for patients with recurrent ovarian cancer.

1 initiation of treatment

Upon joining the study, the patient will begin treatment with olaparib in the form of film-coated tablets. The dosage will be either 150 mg or 100 mg, taken orally. The specific dosage and frequency will be determined by the study protocol and the patient’s condition.

2 chemotherapy administration

The patient may receive chemotherapy drugs such as paclitaxel, carboplatin, gemcitabine hydrochloride, doxorubicin hydrochloride, bevacizumab, and cisplatin. These medications are administered intravenously, meaning they are given through a vein. The specific drugs and their dosages will be determined based on the patient’s treatment plan.

3 monitoring and follow-up

Throughout the trial, the patient’s health and response to treatment will be closely monitored. This includes regular check-ups and tests to assess the effectiveness of the treatment and to identify any side effects. The frequency and type of monitoring will be specified in the study protocol.

4 completion of treatment

The treatment phase will continue until the study’s end date or until the patient completes the prescribed course of treatment. The estimated end date for the trial is December 31, 2026. Upon completion, the patient’s overall health and treatment outcomes will be evaluated.

Who Can Join the Study?

  • Must sign a form agreeing to participate in the study.
  • Must be a female who is at least 18 years old.
  • Must have a type of cancer called high-grade serous or endometroid ovarian, fallopian tube, or primary peritoneal cancer that has come back or is getting worse after initial treatment.
  • Must have had only one previous treatment with a platinum-containing regimen (a type of chemotherapy). Treatments with a drug called bevacizumab are allowed.
  • Must have received a first-line maintenance therapy with a PARPi (a type of medication) for at least 6 months. If the medication used was olaparib, it should not have caused serious side effects or required a permanent dose reduction.
  • Must have had surgery to remove cancer that has come back. The surgery should have removed all visible cancer or at least the cancer that was growing during maintenance therapy.
  • Must have a known BRCA1/2 status (genes related to cancer risk). If the status is unknown, must agree to have it tested before joining the study.
  • Must have a life expectancy of at least 16 weeks.
  • Must start the study treatments within 3 to 8 weeks after the second surgery.
  • Must have an ECOG performance status of 0 to 1, which means being fully active or having some symptoms but still able to carry out light work.
  • Must provide samples from both the first and second surgeries for analysis.
  • Must be able to take medications by mouth.
  • Must have normal organ and bone marrow function, which includes:
    • Hemoglobin level of at least 10.0 g/dL without a blood transfusion in the past 28 days.
    • Absolute neutrophil count (ANC) of at least 1.5 x 109/L.
    • Platelet count of at least 100 x 109/L.
    • Total bilirubin level of no more than 1.5 times the normal limit.
    • AST and ALT levels of no more than 2.5 times the normal limit (or 5 times if there are liver metastases).
    • Creatinine clearance of at least 51 mL/min, which measures kidney function.
    • If not on blood thinners, INR or aPTT should be no more than 1.5 times the normal limit. If on blood thinners, specific ranges apply.
  • Must be postmenopausal or have proof of not being able to have children, confirmed by a negative pregnancy test before starting the study.

Who Cannot Join the Study?

  • Patients who have not undergone secondary cytoreductive surgery for their recurrent or progressive ovarian cancer. This is a surgery to remove as much of the cancer as possible after it has returned or continued to grow.
  • Patients who are not female, as the study is only for women.
  • Patients who are part of a vulnerable population, meaning those who might need special protection or care, are not included in this study.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
IRCCS Humanitas Research Hospital Rozzano Italy
Azienda Ospedaliero Universitaria Careggi Florence Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Azienda Ospedaliera Universitaria Universita’ Degli Studi Della Campania Luigi Vanvitelli Naples Italy
Ente Ecclesiastico Ospedale Generale Regionale Miulli Acquaviva Delle Fonti Italy
Azienda Ospedaliero Universitaria Di Sassari Sassari Italy

Other Sites

Site Name City Country Status
Ospedale San Raffaele S.r.l. Milan Italy
IRCCS Istituto Nazionale Tumori Fondazione Pascale Naples Italy
Ospedale S G Moscati Statte Italy
Centro Di Riferimento Oncologico Di Aviano Aviano Italy
ARNAS Civico Di Cristina Benfratelli Palermo Italy
University Hospital Consorziale Policlinico Bari Italy
Isvowowu Rngxriuhq Pdr Lk Saycig Dmm Trmeil Diqf Anuzatk Ithr Sfxfsp Meldola Italy
Uchutmvareoqiaqor Dpzuw Snads Dj Vmkdsa Verona Italy
Aateqcl Obmhizketgf Uydoihyfagvur Ffcilzwh Iv Dr Nfhulz Naples Italy
Aedveaw Ofwuvkwazslrnxznbjhblqgtv Mixyzien Dwqws Chdrid Novara Italy
Ajibfzp Uajvc Swfsuxxzb Lyedov Ds Bmwrmek Bologna Italy
Idlnckym Osnqyjzktf Vyzzqe Padua Italy
Osgzzhff Vyot Fiqgx Lodbg Lecce Italy
Ofhljlhw Sjpnb Myios dktof Mhuohgjiffsm Udine Italy
Iywzq Ixvkeqgd Fhoywhiklmocm Okqykmcrunmz Izbzdyap Nvindrtmk tjcdpo Rmmdrh Esogl Rome Italy
Ogpazykz Gxcvewiho Catania Italy
Orslldmg Sciqv Maqqm Dsonf Melyuqbjsopv &cdxhbj Abxiehz Oeyoplbqfab dg Pvadrht Perugia Italy
Izsenpvd Dt Coyoywax Fwjefhjeyw Dah Pxxqbnet Pnm Ltuptnwiiv Iafpw Candiolo Italy
Ayanvlr Ofjbjlwggak Plt Lhmfzawmsskkzcaww Cppixdmgeq Catania Italy
Ahtpyzovqc Mwqgscn Hexfrbyo Lecco Italy
Athzmwy Uaw Izdvj Dr Rglkay Eseyai Reggio Emilia Italy
Aptzlml Utg Tlchndo Sxi Egz Arezzo Italy
Avkctsa Ugrmc Siazujbfk Lzwmwr Dctpm Rfcyosg Faenza Italy
Aowxkqd Okgnjmusnaj Unzwxtjgppsfk Pojrp Parma Italy
Arcpjjc Pqcpschmrqa Ppr I Sfvuscn Shwmeian Trento Italy
Ubqvywuwweuhtvhgv Dx Phtp Pisa Italy
Aaqyhpu Ugjxkccdhiol Lpqtcn Szqjc Siikabwew Ny 2 Matsi Tmqqkmbeqj Treviso Italy
Amzlwll Uumuf Lcbwsw Szsqc Sawvgnkln N 8 Bgpxhp Vicenza Italy
Abdqcpa Oipthldbsbv Ozlvxj Matttdrxzf Dv Twvulg Turin Italy
Amhslfn Srxfxwoni Liqcgc Al Du Ajvxcvmayqs Alexandria Italy
Atodplz Oucvyiekfkm Umrpeoamalhcm Mqjci Dbyfrb Catanzaro Italy
Axyp Rxbxhekplegzgccds Ovvqbosslup dp Rhg Rho Italy

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Italy Italy
Recruiting
22.03.2023

Trial locations

Investigated Drugs:

Olaparib is a medication used in this trial to see if it can help patients with recurrent ovarian cancer live longer without the disease getting worse. It is being tested to see if it works better than the usual chemotherapy after patients have had surgery to remove as much of the cancer as possible. Olaparib is a type of targeted therapy known as a PARP inhibitor, which works by preventing cancer cells from repairing themselves, leading to their death.

Investigated Diseases:

Recurrent Ovarian Cancer – This disease occurs when ovarian cancer returns after a period of remission. It typically involves the reappearance of cancerous cells in the ovaries or other areas of the body after initial treatment. The progression of recurrent ovarian cancer can vary, with some patients experiencing slow growth of cancer cells, while others may have a more rapid progression. Symptoms may include abdominal pain, bloating, and changes in bowel habits. The disease often requires further medical intervention to manage its progression.

Trial ID:
2024-516842-21-00
NCT ID:
NCT05255471
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Italy The Netherlands Spain

  • Study of Sacituzumab Tirumotecan and Bevacizumab for Patients with Recurrent Ovarian Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Belgium Czechia Denmark Finland France +8